Fox Run Management, L.L.C. Aerie Pharmaceuticals Inc Transaction History

Fox Run Management, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 17, 2019	BUY	$28.97 - $48.21 $270,521 - $450,184	9,338 New	9,338 $276,000
Q4 2018 Jan 15, 2019	SELL	$33.0 - $60.04 $107,877 - $196,270	-3,269 Closed	0 $0
Q3 2018 Oct 05, 2018	BUY	$56.15 - $73.9 $183,554 - $241,579	3,269 New	3,269 $201,000
Q2 2018 Jul 17, 2018	SELL	$47.85 - $70.45 $196,759 - $289,690	-4,112 Closed	0 $0
Q1 2018 Apr 17, 2018	BUY	$51.15 - $61.0 $210,328 - $250,832	4,112 New	4,112 $223,000
Q4 2017 Jan 18, 2018	SELL	$50.85 - $65.1 $371,205 - $475,229	-7,300 Closed	0 $0
Q3 2017 Oct 23, 2017	BUY	$48.6 - $60.1 $354,780 - $438,730	7,300	7,300 $355,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.